Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer.
Virus-like particles (VLPs) are self-assembling, non-replicating particles lacking the viral genome that are formed by one or several viral structural proteins. VLPs can be purified after expression in yeast cells, insect cells using baculoviruses, Escherichia coli or mammalian cells. Recently, vaccines based on VLPs have come into focus with the FDA approval of a VLP-based vaccine against human papilloma viruses. However, this application of VLPs is just one of many developments within the VLP field. Other potential applications under development besides vaccines against viruses or cancers also include gene delivery and treatment of different disorders.
Department of Oncology-Pathology, Karolinska Institutet, Cancer Centrum Karolinska, Stockholm, Sweden. torbjorn.ramqvist@ki.se
Torbjörn
T
Ramqvist
Kalle
K
Andreasson
Tina
T
Dalianis
D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D036022:Capsid Proteins / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology / Q000821:virology; D018984:Epitopes, T-Lymphocyte; D015316:Genetic Therapy; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000628:therapy*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D014611:Vaccination; D014771:Virion / Q000276:immunology*
D016915:AIDS Vaccines; D036022:Capsid Proteins; D018984:Epitopes, T-Lymphocyte; D017325:Hepatitis B Vaccines; D053918:Papillomavirus Vaccines